11 – 20 of 25
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
COVID-19 and ANCA-associated vasculitis : Recommendations for vaccine preparedness and the use of rituximab
(
- Contribution to journal › Letter
-
Mark
Rituximab in Membranous Nephropathy
(
- Contribution to journal › Scientific review
- 2020
-
Mark
Recommendations for the management of patients with immune-mediated kidney disease during the severe acute respiratory syndrome coronavirus 2 pandemic
(
- Contribution to journal › Article
-
Mark
Effect of Treatment on Damage and Hospitalization in Elderly Patients with Microscopic Polyangiitis and Granulomatosis with Polyangiitis
(
- Contribution to journal › Article
-
Mark
Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?
(
- Contribution to journal › Scientific review
- 2018
-
Mark
Manifest för lämplig styrning av hälso- och sjukvården
(
- Contribution to journal › Debate/Note/Editorial
- 2017
-
Mark
Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis
(
- Contribution to journal › Article
-
Mark
Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody-associated vasculitis
(
- Contribution to journal › Letter
- 2015
-
Mark
Outcome and Treatment of Elderly Patients with ANCA-Associated Vasculitis.
(
- Contribution to journal › Article
-
Mark
Slutreplik, Diana Karpman och medförfattare : - NT-rådet bör omedelbart återkalla sitt beslut om eculizumab
(
- Contribution to journal › Debate/Note/Editorial